Latest News
& Press Releases

The approval, which was made under Priority Review, is a watershed moment in gene therapy as it marks the first FDA green light for a lentiviral vector.

The global Pharmacogenomics Market is expected to reach USD 11.97 Billion by 2027, according to a new report by Emergen Research.

According to the current analysis of Emergen Research, the Metastatic urothelial carcinoma market was valued at USD 725.9 million in 2019 and is expected to reach USD 2.71 billion by the year 2027, at a CAGR of 17.9%.

According to the current analysis of Reports and Data, the global Phototherapy market was valued at USD 554.6 Million in 2020 and is expected to reach USD 784.0 Million by year 2028, at a CAGR of 4.6%.

Researchers at Case Western University looked at the real-world experiences of 13,644 patients who were treated with Paxlovid or Lagevrio (molnupiravir) during the first half of 2022.

Ryvu and Opthea have new funding to work with, Tessa Therapeutics and Enlivex kick off new trials and Revive Therapeutics amends the Phase III protocol for its COVID-19 hopeful.

The Global Anxiety Disorder and Depression Treatment Market size is forecast to reach USD 19.53 Billion by 2028, registering a CAGR of 2.4% over the forecast period, according to a new report by Reports and Data.

Wilmington, Delaware, United States, Transparency Market Research Inc. – An antibody, also known as an immunoglobulin, is a large Y-shaped protein produced by B-cells.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Women’s health diagnostics are used to analyze and detect health issues in women such as breast cancer, cervical cancer, fertility & pregnancy testing, and infectious disease testing.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Sacroiliac joints (SI) are joints between the sacrum and ilium bones of the pelvis.

Kriya Therapeutics tapped longtime pharma veteran Pedro Huertas as chief medical officer of its rare disease division.

Researchers recently developed a peptide called A1R-CT that could ultimately have therapeutic applications in both epilepsy and Alzheimer’s disease.

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments